Skip to main content

Table 1 – Patient characteristics at enrolment (safety population, n = 1293)

From: No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study

Indication

Pretreatment

Total, n (%)

Male, n (%)

Female, n (%)

Mean age (± SD) years

Mean BMI (± SD)a kg/m2

Isolated GHD

Naïve

94 (7.3)

39 (3.0)

55 (4.3)

46.9 (15.4)

29.7 (6.6)

Pretreated

61 (4.7)

27 (2.1)

34 (2.6)

42.7 (16.2)

31.3 (8.8)

MPHD

Naïve

537 (41.5)

289 (22.4)

248 (19.2)

49.5 (14.7)

29.7 (6.3)

Pretreated

591 (45.7)

305 (23.6)

286 (22.1)

50.4 (15.6)

29.0 (6.2)

Other

Naïve

6 (0.5)

4 (0.3)

2 (0.2)

44.9 (13.1)

29.0 (0.6)

Pretreated

4 (0.3)

2 (0.2)

2 (0.2)

31.7 (9.1)

26.0 (5.7)

Total

 

1293 (100.0)

666 (51.5)

627 (48.5)

49.3 (15.3)

29.4 (6.4)

  1. BMI body mass index; GHD growth hormone deficiency; MPHD multiple pituitary hormone deficiency; SD standard deviation
  2. an = 1092 patients with BMI recorded at enrolment